LABP News and Press, Landos Biopharma Inc. From 05/12/23

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical...

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical...

2023-03-23 09:15:04 ET Landos Biopharma press release ( NASDAQ: LABP ): Q4 GAAP EPS of -$0.13 beats by $0.04 . cash and cash equivalents as of December 31, 2022 of $36.64 million. For further details see: Landos Biopharma GAAP EPS of -$0.13 beats by $0.04

On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into First Half of 2025 NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, I...

Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13 Company Remains On-Track to Initiate the NX-13 Phase 2 Proof-of-Concept Trial in Ulcerative Colitis in the Second Quarter of 2023 NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -...

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that an abstract on its Pha...

Landos Biopharma ( NASDAQ: LABP ) announced a $16.7M private placement financing from the sale of pre-funded warrants to purchase an aggregate of 30.9M shares at a price per pre-funded warrant of $0.54 to entities associated with Perceptive Advisors, Landos’ largest stockholder...

Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued De...

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a $16.7 million private pla...

Hot Penny Stocks To Buy For Under $3 Are you looking for penny stocks to buy today? You’re not alone, and the process of finding them isn’t as easy as you might think. One of the main reasons is the much higher volatility in the stock market today. It isn’t just penny s...